



Andres Romero, M.D.

50 Woodside Plaza
Suite 818
Redwood City, CA
94061

(475) 227 9347

andres.romero.md@gmail.com

- Experienced Infectious Diseases physician with training completed at Yale-New Haven Hospital and Memorial Sloan Kettering Cancer Center
- Inpatient and outpatient experience providing infectious diseases care in academic institutions and private community hospitals
- Leadership experience as medical director for infectious diseases, antimicrobial stewardship and infection prevention and control

- Expertise in hospital administration overseeing utilization management, quality of care and patient safety
- Leadership experience in hospital surveys and protocol optimization for regulatory compliance and accreditation
- Experience designing patient care protocols for acute care and post-acute care facilities (long-term acute care hospitals, skilled nursing facilities and nursing homes)
- Direct involvement in optimization of transitions of care (transfers and discharges from the hospital)

- Active involvement in medical staff credentialing and development of physician peer review protocols for affiliated medical providers

- Core Faculty and educator for an Internal Medicine Residency Program

Board Certification

American Board of Internal Medicine 2014

American Board of Internal Medicine Infectious Disease 2016

Active Medical License: California

Employment Experience/Leadership Roles

Chief Health Officer
AHMC Seton Medical Center, Daly City, CA
November 2023 - Present

Infectious Diseases Medical Director/Infectious Diseases Division Chief
Antimicrobial stewardship and Infection Prevention director
AHMC Seton Medical Center and AHMC Seton Coastsides, Daly City, California

Infectious Diseases Specialist/Consultant
Apollo Medical Group, Alhambra, CA

Employee Health Medical Director
AHMC Seton Medical Center, Daly City, CA
January 2021 - Present

Core Faculty - NEMS Internal Medicine Residency Program
July 2023-Present

Chair - Department of Medicine

AHMC Seton Medical Center, Daly City, CA
July 2022 - January 2023

COVID-19 Medical Director
Infection prevention and Antibiotic Stewardship co-director
Providence Saint Johns Health Center, Santa Monica, CA

Infectious Diseases Specialist/Consultant
Doctor's Of Saint Johns Medical Group
Saint John's Physicians Partners, Santa Monica, CA
August 2019- December 2020

Infectious Diseases Medical Director
Infection Prevention and Antibiotic Stewardship Director
Cadia Healthcare, Hyattsville, MD

Internal Medicine and Primary Care Provider
Cadia Healthcare, Hyattsville, MD
July 2016 - July 2019

Education

Memorial Sloan Kettering Cancer Center, New York, NY
Clinical Fellowship Infectious Diseases (2014 - 2016)

Yale School of Medicine, Yale-New Haven Hospital, New Haven, CT
Residency in Internal Medicine (2011 - 2014)

Our Lady of Rosary School of medicine, Bogota, Colombia
Doctor of Medicine, with honors (2003 – 2009)

Awards and Grants

- 2014 Award for the best research presentation. Department of Medicine Annual senior Residency Research seminar. Yale New Haven Hospital.
- 2014 Award for outstanding efforts in Research. Yale New Haven Medical Center. Department of Medicine
- 2013 Peer Recognition Award. Yale-New Haven Medical Center. Saint Raphael Program. Department of Medicine. Best resident elected by the class of interns 2012-2013.
- 2010 Young Researcher Award. Grant from the Colombian government equivalent to 12,000 USD to pursue research in *H. Pylori pathogenesis for 12 months*.
- 2009 Honor Medal "José Vicente Castro Silva". Best Alumni, 2009 medicine class. Highest award given annually by the medical school.

Research Experience

2020

A Phase III, Randomized, Double-Blind, Multi center Study to Evaluate The Efficacy of Remdesivir Plus Tocilizumab Compared with Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia

Co-Principal Investigator

Roche

Site: Providence St John's Health Center

A phase 2, randomized, placebo-controlled, participant and investigator blinded, multi-center study to assess efficacy and safety of MAS825 for the treatment of SARS-COV-2 infected patients with COVID-19 pneumonia and impaired respiratory function

Co-Principal Investigator

Novartis

Site: Providence St John's Health Center

An adaptive, phase 2/3 randomized, double-blind, placebo-controlled study assessing the safety and efficacy of Anti-Spike SARS cOV 2 monoclonal antibodies for the treatment of hospitalized patients with COVID-19.

Co-Principal Investigator

Regeneron

Site: Providence St John's Health Center

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in participants with severe COVID-19

Co-Principal Investigator

Gilead Sciences

Site: Providence St John's Health Center

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in participants with moderate COVID-19

Co-Principal Investigator

Gilead Sciences

Site: Providence St John's Health Center

An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study assessing efficacy and safety of Sariilumab for Hospitalized patients with COVID-19

Co-Principal Investigator

Regeneron Pharmaceuticals INC

Site: Providence St John's Health Center

2010 (June – October) Research trainee

Toll-like receptors and their role in the pathogenesis of transplant infections.

Mayo Clinic, Rochester, MN.

Experience performing RT-PCR, classic PCR, gene sequencing, and management of cell cultures.

2010 (April – June) Clinical Sub-Investigator

Celtura® (Influenza A H1N1 vaccine) observational safety study.

Novartis, Bogota, Colombia

Protocol development, patient enrollment and follow-up.

2009 (August 2009– March 2010) Principal investigator

Description of current learning theories according to students and teachers perspectives: Validation of a new scale in the assessment of teaching-learning experiences

Romero FA., Isaza, A.

Universidad del Rosario, School of Medicine

Bogota, Colombia

Protocol development. Data collection and analysis. Internal presentation of results and participation in curriculum development for the medical school.

2009 (October 2009 – March 2010). Research assistant

H pylori genotypic variations and their association with risk factors, clinical presentation and antimicrobial susceptibilities in a reference center from Bogota, Colombia.

Quintero G, Romero FA. Research in progress.

Universidad del Rosario, School of Medicine

Bogota, Colombia

Protocol development and patient enrollment.

Teaching activities and mentoring experience

Core Faculty
North East Medical Services (NEMS) Internal Medicine Residency Program
Daly City, CA
July 2023 - Present

Tutor: Clinical genetics
Mentorship of second year medical students providing guidance and support during the transition to clinical practice.
“Fellow tutors” training course to improve leadership and mentoring skills
Bogota, Colombia 2007

Bibliography, Publications and Oral presentations

1. **Romero FA**, Deziel PJ, Razonable RR. Majocchi's granuloma in solid organ transplant recipients. *Transpl Infect Dis.* 2011 Aug;13(4):424-32.
2. **Romero FA**, Razonable RR. Infections after liver transplantation. *World J Hepatol.* 2011 Apr 27;3(4):83-92.
3. **Romero FA**, Franco-Vega M, Golden M. *Pseudomonas aeruginosa* Pneumonia complicating acute supraglottitis. Saint Raphael Hospital. New Haven, CT. Poster presentation American College of Physicians. Connecticut Chapter 2011.
4. **Romero FA**, Fisher A. Skin Bumps: MRSA is not the worst thing that can happen. Rapid growing mycobacteria infection. Yale-New Haven Medical Center. Saint Raphael Campus. Poster presentation American College of Physicians. Connecticut Chapter 2012.
5. **Romero FA**, Boyce JM. Effect of Intravenous Vancomycin Use on Methicillin-Resistant *Staphylococcus aureus* (MRSA) Nasal Surveillance Cultures Among Hospitalized Patients. Abstract. Poster Presentation American college of physicians. Connecticut Chapter 2013.
6. Perez EA, Eisenstein C, Schneider WJ, Castillo MA, Lacaille S, Lucca A, **Romero FA**, Low S, Seo SK, Brown A. Three Month Treatment for Latent Tuberculosis Infection (LTBI) with Rifapentine and INH (R&I) in a Medical Center Employee Health Service (EHS)- Strategy and Advantages. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY. Poster presentation IDWeek 2015.
7. Latent Tuberculosis Infection (LTBI) among Healthcare Workers (HCWs): The Memorial Sloan Kettering Cancer Center (MSK) Experience. Perez EA, Eisenstein C, Schneider WJ, Castillo MA, Lacaille S, Lucca A, **Romero FA**, Low S, Seo SK, Brown A. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY. Poster presentation IDWeek 2015.
8. Morjaria S, Epstein DJ, **Romero FA**, Taur Y, Seo SK, Papanicolaou GA, Hatzoglou V, Rosenblum M, Perales MA, Scordo M, Kaltsas A. Toxoplasma Encephalitis in Atypical Hosts at an Academic Cancer Center. *Open Forum Infect Dis.* 2016 Mar 30;3(2)
9. **Fabian Andres Romero, MD** ; Susan Seo, MD, FIDSA ; Ying Taur, MD, MPH ; Craig Sauter, MD ; Jae Park, MD ; Tobias M. Hohl, MD, PhD, FIDSA. Infections presenting 30 days after Chimeric Antigen Receptor (CAR) Modified T-cells: A Single-center Experience. Oral presentation. IDWeek 2016. New Orleans, LA.
10. Del Castillo M, **Romero FA**, Argüello E, Kyi C, Postow MA, Redelman-Sidi G. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint

Blockade for the Treatment of Melanoma. Clin Infect Dis. 2016 Dec 1;63(11):1490-1493. Epub 2016 Aug 7.

11. Umiak SC, **Romero FA**, Schwegman P, Fitzpatrick V, Connor M, Brown AE, Kamboj M. Utilization of Electronic Health Record Events to Conduct Tuberculosis Contact Investigation in a High-Risk Oncology Unit. Infect Control Hosp Epidemiol. 2017 Aug 10:1-5
12. **Romero FA**. Impact of Antibiotic Stewardship Program in Long-term Care Facilities: A Nursing Home Network Experience. Oral Presentation, IDWeek 2017. San Diego, CA.
13. **Romero FA**, Powell EA, Babady NE, Kaltsas A, Figueroa CJ, Pulitzer M, Mehrara BJ, Glickman MS, Morjaria S. Nontuberculous Mycobacterial Infections After Silicone Breast Implant Reconstruction Emphasize a Diversity of Infecting Mycobacteria. Open Forum Infect Dis. 2017 Sep 2;4(4)2017
14. Park JH, **Romero FA**, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, Seo SK. Cytokine Release Syndrome Grade is a Predictive Marker for Infections in Relapsed or Refractory B-cell All Patients Treated with CAR T Cells. Clin Infect Dis. 2018 Feb 22. [Epub ahead of print]
15. Kesari S, Hammond, T. **Romero FA**, Tankovich, N. Intravenous Mesenchymal Stem Cells for COVID-19 Acute Lung Injury. Manuscript submitted.
16. Araque, KA. Sriram, G. **Romero FA**, Soldin, S. Steroid and Thyroid hormone profile in patients admitted with COVID-19. Manuscript submitted.

Updated: April 2024

NOT YET REVIEWED